CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...